Duvortuxizumab
- Generic Name
- Duvortuxizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1831098-91-9
- Unique Ingredient Identifier
- J545GSE96Y
- Background
Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT02743546
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath